PHOENIX ― Gastrointestinal cancers are some of the most commonly diagnosed cancers, and they continue to be associated with poor survival outcomes. The drug adagrasib specifically targets the KRASG12C gene mutation that is common in gastrointestinal cancers and inhibits gastrointestinal function.
Trending
- Pfizer’s $10B monthly GLP-1 bet generates competitive weight loss in phase 2b (Fierce Biotech)
- ‘AI-native’ outpatient surgery startup Oath Surgical inks Nvidia partnership (Fierce Biotech)
- NVIDIA, Oath Surgical, ASCs and the Future of Physical AI in Healthcare (LSI | LinkedIn)
- UMass Successfully Performs Its First Full-Thickness Resection Device Procedure (UMass Chan Medical School)
- 5 gastroenterology physician moves in 1 month (Becker’s GI & Endoscopy)
- Artificial Intelligence on Trial: Who’s Liable When Clinical Algorithms Go Wrong? (Medscape)
- Building the Future Gastroenterologist: Why Nutrition and Lifestyle Medicine Must Be Core Competencies (ACG Case Reports Journal)
- Spray Cryotherapy Esophageal Consortium Consensus Recommendations for Liquid Nitrogen Spray Cryotherapy in Barrett’s Esophagus and Esophageal Cancer Using a Modified Delphi Process (The American Journal of Gastroenterology)
